November 8, 2006 – Catalyst Pharmaceutical Partners priced 3.35 million shares at $6 for its IPO, down from a range of $11-$13; a Human Genome Sciences cancer drug passed its safety and tolerability tests; Dendreon said Provenge, its prostate cancer vaccine, lengthened the PSA doubling times by 35%; Biogen Idec began selling MS drug Avonex in Japan; Bradley Pharma will sell Bio-E-Gel, an estradiol transdermal gel, in the US for BioSante Pharma; Novovax said its virus-like particle pandemic influenza vaccine triggered a protective immune response; an anticancer drug from Exelixis showed efficacy against tumors, but dosing was limited by side effects; and Hollis-Eden Pharma placed $26 million worth of common stock at $6.50 a share. The Centient Biotech 200™ moved up 6 points to 4014, a rise of .15%. More details...
